Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880171 | 0.90 | TDP1 (0.54) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL6939488 | 0.89 | TDP1 (0.57) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL423505 | 0.87 | TDP1 (0.59) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL21423964 | 0.87 | TDP1 (0.59) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL9677520 | 0.86 | TDP1 (0.41) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL23061330 | 0.85 | TDP1 (0.42) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL1784924 | 0.84 | CTSK (0.51) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL6939520 | 0.84 | TDP1 (0.44) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL21423607 | 0.84 | TDP1 (0.53) | TDP1GAAMEN1KMT2ACA12 | |
| SCHEMBL2799440 | 0.83 | TDP1 (0.56) | TDP1GAAMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| EP-4041735-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | Biohaven Therapeutics Ltd. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | SEIKAGAKU CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2020-05-07 | — | — | US | disclosed |
| WO-2019189876-A1 | (CARBOXYLIC ACID-TYPE COMPOUND)-POLYMER CONJUGATE HAVING BIOLOGICAL ACTIVITY, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-7674912-B2 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2010-03-09 | — | — | US | disclosed |
| EP-1877391-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. Lundbeck A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
| WO-2006114093-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | HCAR1, HCAR2, MCCC2 | TDP1 4178/4885GAA 46/4885MEN1 2134/4885 |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SOAT1, SLC7A1, ODC1 | TDP1 3454/4885GAA 3994/4885MEN1 236/4885 |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA2B, ADORA1 | TDP1 2150/4885GAA 2501/4885MEN1 1436/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | TDP1 134/4885GAA 44/4885MEN1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.